Can B Corp. (OTCQB:CANB), through Nascent Pharma Holdings, Inc., has announced its retention of Fox Rothschild, a U.S. based law firm, to lead the monetization efforts of its two cannabis patents. These patents, valued at $122 million in December 2020, could potentially be worth up to $750 million when considering the global THC and CBD markets. The patents have survived an invalidity challenge in Federal Court, underscoring their robustness and the innovative nature of the formulations they cover.
The patents pertain to the extraction of pharmaceutically active components from cannabis, specifically targeting formulations where cannabinoids constitute more than 95% of the composition. This includes a wide range of products such as beverages, tinctures, vape pen liquids, and liquid-filled capsules, representing a significant portion of the hemp and cannabis industry. Additionally, the method-of-use patent outlines potential applications in managing conditions like cancer, IBS, chronic pain, PTSD, anxiety, sleep disorders, and opioid dependencies, highlighting the therapeutic potential of these patents.
The engagement of Fox Rothschild, with James Smedley at the helm, signifies a strategic move by Can B Corp. to capitalize on its intellectual property in a rapidly growing industry. The firm's extensive legal expertise is expected to navigate the complexities of patent monetization, potentially unlocking substantial value for the company and its stakeholders. This development not only underscores the economic impact of cannabis and psychedelic industries but also highlights the importance of intellectual property in fostering innovation and therapeutic advancements.
